## Page 1 of 5

INFORMATION	Atty Docket No: P11089.02	Serial No.: 10/852.997	
DISCLOSURE		·	
STATEMENT	Applicant(s): William F. Kae	mmerer	
0 8 2006 8)	Filing Date: 25-May-04	Group: 1635	

**US PATENT DOCUMENTS** 

Examiner Initial	+/*	Document Number	Date .	Name of Patentee or Applicant of Cited Document	Class	SubClass	Filing Date I Appropriate
LW		US 01/0027309	04-Oct-01	Elsberry, Dennis D.			01-Jan-01
		US 02/0068093	06-Jun-02	Trogolo, Jeffrey A., et al	424/618		29-Aug-01
		US 04/0023390	05-Feb-04	Davidson, et al.			
	+	US 05/042646	24-Feb-05	Davidson, et al.			<del></del>
		US 4683195	28-Jul-87	Mullis, Kary B., et ai	435/6		07-Feb-86
		US 4683202	28-Jul-87	Mullis, Kary B.	435/91	·····	25-Oct-85
		US 4800159	24-Jan-89	Mullis, Kary B., et al	435/172.3		17-Dec-86
		US 4965188	23-Oct-90	Mullis, Kary B. et al	435/6		17-Jun-87
		US 5354326	11-Oct-94	Comben, Richard H. et al	607/115		27-Jan-93
		US 5624803	29-Apr-97	Noonberg, Sarah et al	435/6		13-Oct-94
-1 "		US 5720720	24-Feb-98	Laske, et al.	604/49		15-Mar-96
		US 5735814	07-Apr-98	Elsberry, Dennis D. et al.	604/43		30-Apr-96
		US 5782892	21-Jul-98	Castle, Vernon P. et al	607/37		25-Apr-97
		US 5814014	29-Sep-98	Elsberry, Dennis D., et al.	604/43		29-Jul-97
		US 6042579	28-Mar-00	Elsberry, Dennis D., et al.	604/891.1		30-Apr-97
		US 6093180	25-Jul-00	Elsberry, Dennis D.	604/506		18-Aug-97
		US 6180613	30-Jan-01	Kaplitt, et al.	514/44		06-Jun-95
		US 6187906	13-Feb-01	Gluckman, et al.	530/331		15 <b>-J</b> un-99
		US 6245884	12-Jun-01	Hook, Vivian Y.H.	530/300		16-Oct-98
		US 6281009	28-Aug-01	Boyce, Frederick M.	435/321.0		11-Sep-97
		US 6300539	09-Oct-01	Morris, Christopher M.	800/9		
		US 6310048	30-Oct-01	Kumar, Vijaya			,
		US 6313268	06-Nov-01	Hook, vivian Y.H.	530/350		20-Apr-99
		US 6319905	20-Nov-01	Mandel, et al.	514/44		19-May-99
		US 6343233 B1	29-Jan-02	Werner, Robert I., et al	607/119		09-Sep-98
		US 6372721	16-Apr-02	Neuman, et al.	514/44		30-Sep-99
		US 6376471	23-Apr-02	Lawrence, III, et al.	514/44	-	08-Oct-98
		US 6436392	20-Aug-02	Engelhardt, et al.	424/93.2		25-Mar-99
		US 6468524	22-Oct-02	Chiorini, John A.	424/93.21		22-Mar-00
$\Delta$		US 6551290	22-Apr-03	Elsberry, et al.			31-Mar-00

**EXAMINER** 

**Date Considered** 

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communciation to applicant.

Reference Previously cited and provided to the Examiner.

+ - New Reference not previously cited (available copies included).

Based on Form PTO-FB-A820 (Also form PTO-1449)

Patent and Trademark Office, U.S. Department of Commerce

	US 6594880	22-Jul-03 Elsberry, Dennis		23-May-01
--	------------	----------------------------	--	-----------

## FOREIGN PATENT DOCUMENTS

Examiner Initial	+/*	Document Number	Date	Name	Class	SubClass	Filing Date If Appropriate
LW I		WO 00/30567	02-Jun-00	Healthshield Technologies, Inc.			16-Nov-99
		WO 00/64505	02-Nov-05	Healthshield Technologies, L.L.C.			27-Apr-00
<del> </del>		WO 01/16312A2	08-Mar-01	Ribozyme Pharmaceuticals, Inc.	C12N 15/11	-	30-Aug-00
	· · · - · - ·	WO 01/49844 A1	12-Jul-01	Rutgers, The State Univ of NJ	C12N 15/11		02-Jan-01
		WO 01/60794A2	23-Aug-01	The Regents of the Univ of CA	C07D		20-Feb-01
		WO 01/91801 A2	06-Dec-01	Chiron Corporation	A61K 48/00		25-May-01
		WO 02/07810	31-Jan-02	Medtronic, Inc.			
		WO 03/047676 A1	12-Jun-03	Medtronie, Inc.	A61M 25/00	- · · · · · -	26-Nov-02
		WO 03/053516 A1	03-Jul-03	Medtronic, Inc.	A61N 1/375		18-Dec-02
		WO 03/070895 A2	28-Aug-03	Ribozyme Pharmaceuticals	C12N		18-Feb-03
		WO 03/099298 A1	04-Dec-03	Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.	A61K 31/7105		26-May-03
		WO 04/013280	12-Feb-04	University of Iowa Research Foundation			
		WO 04/041101	21-May-04	Medtronic, Inc.			27-Oct-03
		WO 04/047872	10-Jun-04	Medtronic, Inc.			
	+	WO 04/058940	15-Jul-04	University of Iowa Rescarch Foundation			
		WO 04/084955	07-Oct-04	Medtronic, Inc.			18-Mar-04
		WO 04/101063	25-Nov-04	Medtronic, Inc.			08-Mar-04
	+	WO 04/101787	25-Nov-04	Japan Science and Technology Agency			
	+	WO 05/045034	19-May-05	Sirna Therapeutics, Inc.			
		WO 93/23569	25-Nov-93	Ribozyme Pharmaceuticals, Inc.	C12Q 1/68		29-Apr-93
		WO 94/02595	03-Feb-94	Ribozyme Pharmaceuticals, Iuc.	C12N 5/22		02-Jul-93
V		WO 9618736	20-Jun-96	Ribozyme Pharmaceuticals, Inc.	C12N 15/52		22-Nov-95
EXAMINER			Date	Conside	ered		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communciation to applicant.

<sup>\* -</sup> Reference Previously cited and provided to the Examiner.

<sup>+ -</sup> New Reference not previously cited (available copies included).

LW	WO 97/40874	06-Nov-97	Medironic, Inc.	A61M 5/172,	30-Apr-97
LW	WO 99/50300A1	07-Oct-99	The Trustees of the Univ of PA	C07K 16/00	29-Mar-99

## OTHER DOCUMENTS (Including Authors, title, Date, Pertinent Papers, etc.)

Examiner Initial	+/*	Document Cite
LW		Aebischer, Patrick, Recombinant proteins for neurodegenerative diseases: the delivery issue, TRENDS in Neurosciences, 24(9):533-540, 2001.
		Callaban, Michael J., et al, Augmented Senile Plaque Load in Aged Female β-Amyloid Precursor Protein- Transgenic Mice, American Journal of Pathology, 158(3):1173-1177, 2001.
		Caplen, Natasha J., et al., Rescue of polyglutamine-mediaed cytotoxicity by double-stranded RNA-mediated RNA interference, Human Molecular Genetics 11(2):175-184, 2002.
		Chen et al., Multitasrget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequened HIV-1 isolates, Nucleic Acids Res., 20:4581-4589, 1992.
		Chowrira et al., In vitro and in vivo comparison of Hammerhead, Hairpin and Hepatitis delta Virus Self- Processing Ribozyme Cassettes, Journal Biol. Chemistry, 269:25856-25863, 1994.
		Clark, H., et al., Purkinji Cell Expression of a Mutant Allele of SCA1 in transgenic mice leads to disparate effects on motor behaviorsk, followed by a proigressive cerebellar dysfunction and histological alterations, Journal of Neuroscience, 17(19):7385-7395, 1997.
		Couture, Larry A., et al, Anti-gene Therapy: The Use of Ribozymes to Inhibit Gene Function, Trends in Genetics, 12(12):510-515, 1996.
		Davidson, Beverly L., Molecular medicine for the brain: silencing of disease genes with RNA interference, The Lancet Neurology, 3:145-149, 2004.
		Dineley, Kelly T., et al, Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of a7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presentin 1 and Amyloid Precursor Proteins, Journal of Biological Chemistry, 277(25):22768-22780, 2002.
		Dropulic et al., Functional characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency virus Type I Expression, Journal Virology., 66(1):1432-1441, 1992.
		Gau, Jen-Tzer, et al, Stable β-Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice, American Journal of Pathology, 160(2):731-738, 2002.
		Glorioso, Joseph C., Use of HSV vectors to modify the nervous system, Current Opinion in Drug Discovery & Development, PharmaPress Ltd ISSN, 5(2):1367-6733, 2002.
		Good, et al., Expression of small, therapeutic RNAs in human cell nuclei, Gene Therapy, 4:45-54, 1997.
		Goto, J., et al., Suppression of Huntingtin Gene Expression by sIRNA: A Possible therapeutic Tool for Huntington's Disease, Neurology, Lippincoll Williams & Wilkins, Philadelphia, US, 60(5) Suppl 1, March 11 2003 p.A286

EXAMINER	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* - Reference Previously cited and provided to the Examiner.

+ - New Reference not previously cited (available copies included).

LW	Heale, et al., siRNA Target Site Secondary Structure Predictions Using Local Stable Substructures, Nucleic Acids Research, 33(3), 2005.
	Hommel, J.D., et al., Local gene knockdown in the brain using viral-mediated RNA interference, Society for Neuroscience Abstract Viewer and Itinerary Planner 2003, Vol 2003, Abstract No. 325.14, November 8-12, 2003
	Hsiao, Karen, et al, Correlative Memory Deficits, Aß Elevation, and Amyloid Plaques in Transgenic Mice, Science, 274:99-102, 1996.
	Isaeson, et al., Lack of Efficacy of "Naked" Small Interfering RNA Applied Directly to Rat Brain, Scandinavian Physiiological Society, 179:173-177, 2003.
	Izant, Jonathan G., et al., Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA, Science, 229:345, 1985.
	Kaemmerer, W.F. and Puram, S., The potential for allele-specific reduction of ataxin1 expression using small,
	Date of publication not provided
LW	Kashani-Sabet et al., Reversal of the Malignant Phenotype by an Anti-ras Ribozyme, Antisense Res. Dev., 2:3-15, 1992.
	Kawarabayashi, T., et al, Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease, Journal of Neuroscience, 21(2):372-381, 2001.
•	King, D.L., et al, Behavioral Characterization of the Tg2576 Transgenic Model of Alzheimer's Disease Through 19 Months, Physiology & Behavior, 75:627-642, 2002.
•	Kitabwalla, Molz, Ph.D., et al., RNA interfence - a new weapon against HIV and beyond, New England Journal of Medicine, 347(17):1364-1367, 2002.
	Klement, Ivan, et al., Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice, Cell Vol. 95:41-53, 1998.
	L'Huillier, Phillip J., et al., Cytoplasmic delivery of ribozymes leads to efficient reduction in x-lactalbumin mRNA levels in C1271 mouse cells, EMBO Journal, 11(12):4411-4418, 1992.
	Lisziewicz et al., Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS, Proc. National Acad Sci USA, 90:8000-8004, 1993.
د. ا	Liu, et al., Specific inhibition of Huntington's disease gene expression by siRNAs in cultures cells., Proceedings of the Japan Academy, Series B, Physical and Biological Sciences, 79:10(pp293-298) Dec. 2003
	Matilla, A., et al., Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation, Journal of Neuroscience, 18(14):5508-5516, 1998.
	McGarry, Thomas J., et al., Inhibition of heat shock protein synthesis by heat-inducible antisense RNA, Proc. National Academy Science, USA, 83:399, 1986.
	McManus, Michael T., Gene Silencing in Mammals by Small Interfering RNAs, Nature Reviews / Genetics, 3:737-747, 2002.
	Miller, Victor M., Allele-specific silencing of dominant disease genes, PNAS, 100(12):7195-7200, 2003.

## **EXAMINER Date Considered**

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communciation to applicant.

\* - Reference Previously cited and provided to the Examiner.

+ - New Reference not previously cited (available copies included).

Based on Form PTO-FB-A820 (Also form PTO-1449)

Patent and Trademark Office, U.S. Department of Commerce

LW		Naldini, Luigi, Efficient transfer, integration and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector, Proc. National Academy Science, 93:11382-11388, 1996.
		Noonberg, et al., In vivo generation of highly abundant sequence-specific oligonocleotides for antisense and triplex gene regulation, Nucleic Acid Research, 22(14):2830-2836, 1994.
		Ohkawa, et al., Activities of HIV-RNA targeted riboyzmes transcribed from a shot-gun type riboyzme-trimmin plasmid, Nucleic Acids Symp. Ser., 27:15-16, 1992.
		Ojwang, Joshua O., et al., Inhibition of human immunodeficiency virus type-1 expressoin by a hairpin ribozym Proc. National Academy Science USA, 89:10802-10806, 1992.
	+	Sapru, et al., Small interfering RNA (siRNA)-Mediated silencing of alpha-synuclein gene expression., Annual Meeting of the Society of Neuroscience, Abstract 297.9, XP001204566, 2003
		Sarver, Nava et al., Ribozymes as potential anti-HIV-1 therapeutic agents, Science, 247:1222-1225, 1990.
		Scanlon, K.J., et al., Ribozyme-mediated cleavage of e-fos mRNA rduces gene expression of DNA synthesis enzymes and metallothionein, Proc. National Academy Science USA, 88:10591-10595, 1991.
		Stackman, Robert W., et al, Prevention of Age-Related Spatial Memory Deficits in a Transgenic Mouse Model of Alzheimer's Disease by Chronic Ginkgo biloba Treatment, Experimental Neurology, 184:510-520, 2003.
		Sullenger, Bruce and Cech, Thomas R., Tethering Ribozymes to a Retroviral Packaging Signal for Destruction Viral RNA, Science, 262:1566, 1993.
		Taira, Kazunari, et al, Construction of a Novel RNA-Transcript-Trimming Plasmid which can be used Both invitro in Place of Run-off and (G)-Free Transcriptions and in vivo as Multi-Sequences Transcription Vectors, Nucleic Acids Research, 19(19):5125-5130, 1991.
		Thompson, James D., et al., Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter, Nucleic Acids Res., 23(12):2259, 1995.
		Ventura, M., et al, Activation of HIV-Specific Ribozyme Activity by Self-Cleavage, Nucleic Acids Research, 21(14):3249-3255, 1993.
		Weerasinghe, Migara et al., Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human Cl lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIG-1 RNA-specific ribozyme, Journal of Virology, 65(10):5531-5534, 1991.
		Xia, et al., sIRNA-mediated gene silencing in vitro and in vivo, Nature Biotechnology 20:1006-1010, 2002.
	+	Xia, et al., RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia., Nature Medicine, 10:8(816-820) 2004
		Yamamoto, A, et al., Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's Disease, Cell, 101:57-66, 2000.
		Yu et al., A hairpin riboyzme inhibits expression of diverse strains of human immunodeficiency virus type 1, Proc. Natl. Acad Sci. USA, 90:6340-6344, 1993.
1		Yu, Jenn-Yah et al., RNA interference by expression of short-interfering RNAs and bairpin RNAs in mammalis cells, PNAS, 99(9):6047-6052, 2002.

EXAMINER /Louis Wollenberger/ **Date Considered** 12/01/2006

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communciation to applicant.

\* - Reference Previously cited and provided to the Examiner.

+ - New Reference not previously cited (available copies included).

Based on Form PTO-FB-A820 (Also form PTO-1449)